New Partnership to Drive Mass Production of Life-Saving Stem Cells – Commercialization Impact Prize Is First of Its Kind in Canada The McEwen Centre for Regenerative Medicine-Centre for Commercialization of Regenerative Medicine Commercialization Impact Prize will solicit innovative ideas from regenerative medicine scientists working in labs throughout the McEwen Centre. The winning team(s) will be awarded up to $600,000 to pursue research that will determine how to manufacture stem cells for clinical use and drug screening. [McEwen Centre for Regenerative Medicine] Press Release Silence Therapeutics Signs Collaboration with MiReven Pty Ltd to Evaluate Delivery of Novel MicroRNA-Based Therapeutics Silence Therapeutics plc announced that it has signed an agreement with MiReven Pty Ltd to assess the delivery potential of Silence’s proprietary delivery systems with MiReven’s novel microRNA-based therapeutics. [Silence Therapeutics plc] Press Release Pluristem and World Renowned Charité Berlin-Brandenburg Center for Regenerative Therapies Renew Five-Year Collaborative Research Agreement Pluristem Therapeutics, Inc. announced it has renewed a five-year Collaborative Research Agreement with the Berlin-Brandenburg Center for Regenerative Therapy at Charite – University Medicine Berlin. [Pluristem Therapeutics, Inc.] Press Release ThermoGenesis Announces AXP® Product Purchase and Distribution Agreement with Golden Meditech Holdings Limited ThermoGenesis Corp. announced that it has signed a wide ranging product purchase and distribution agreement for its AXP® AutoXpress® (AXP) System used for the processing of stem cells from cord blood with Golden Meditech Holdings Limited. [ThermoGenesis Corp.] Press Release Team Awarded Nearly $1.5 Million to Develop New Approaches to Treat Cancer Scientists from The Scripps Research Institute have been awarded approximately $1.5 million from the National Institutes of Health to identify and develop new therapeutic approaches against a broad spectrum of cancers. [The Scripps Research Institute] Press Release Pluristem Commences U.S. FDA Phase II Clinical Trial for Intermittent Claudication: Duke University Medical Center Is First of Five Sites Already Approved Pluristem Therapeutics, Inc. announced it will initiate Phase II clinical trials in the United States to evaluate the safety and efficacy of its PLacental Expanded cells in the treatment of intermittent claudication. [Pluristem Therapeutics, Inc.] Press Release IntelliCell BioSciences Files Patent Application for a New Mechanical Method to Separate Stromal Vascular Fraction from the Blood Vessels in Adipose Tissue IntelliCell BioSciences, Inc. announced that it has filed a patent application for a new mechanical method to separate stromal vascular fraction from the blood vessels in adipose tissue to be used clinically in regenerative medicine. [PR Newswire Association LLC] Press Release Successful Growth of BioDiem’s Virus in VIVALIS EB66® Cell Line BioDiem Ltd announced successful results from two programs of work carried out by French partner VIVALIS, confirming the ability of BioDiem’s Live Attenuated Influenza Virus to grow in VIVALIS’ proprietary EB66® cell line. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP’s, and recombinant proteins. [VIVALIS] Press Release Anne-Marie Duliege Appointed to Governing Board of California’s Stem Cell Agency Anne-Marie Duliege, MD, Chief Medical Officer of Affymax Inc., has been appointed to the Independent Citizens Oversight Committee, the governing board of California’s stem cell agency, the California Institute for Regenerative Medicine. [California Institute for Regenerative Medicine] Press Release |